<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20240220193753
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20240220193753" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 21 Feb 2024 00:37:54 +0000</lastbuilddate>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Antiplatelet Therapy After PCI: The Art and Science of De-Escalation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377261/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):601-604. doi: 10.1161/CIRCULATIONAHA.123.067767. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377261/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38377261</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067767>10.1161/CIRCULATIONAHA.123.067767</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377261</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Robert F Storey</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antiplatelet Therapy After PCI: The Art and Science of De-Escalation</dc:title>
<dc:identifier>pmid:38377261</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067767</dc:identifier>
</item>
<item>
<title>Correction to: Addressing Structural Racism Through Public Policy Advocacy: A Policy Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):e934. doi: 10.1161/CIR.0000000000001216. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38377260</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001216>10.1161/CIR.0000000000001216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377260</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Addressing Structural Racism Through Public Policy Advocacy: A Policy Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38377260</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001216</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):627-632. doi: 10.1161/CIRCULATIONAHA.124.068812. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38377259</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068812>10.1161/CIRCULATIONAHA.124.068812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377259</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38377259</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068812</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18248</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377258/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):e935. doi: 10.1161/CIR.0000000000001215. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377258/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38377258</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001215>10.1161/CIR.0000000000001215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377258</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18248</dc:title>
<dc:identifier>pmid:38377258</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001215</dc:identifier>
</item>
<item>
<title>Poker and Cardiology: Judging Our Decisions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):560-561. doi: 10.1161/CIRCULATIONAHA.123.067366. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38377257</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067366>10.1161/CIRCULATIONAHA.123.067366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377257</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Marcos F Mills</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Poker and Cardiology: Judging Our Decisions</dc:title>
<dc:identifier>pmid:38377257</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067366</dc:identifier>
</item>
<item>
<title>Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377256/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):635-637. doi: 10.1161/CIRCULATIONAHA.123.065330. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377256/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38377256</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065330>10.1161/CIRCULATIONAHA.123.065330</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377256</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Shea E Hogan</dc:creator>
<dc:creator>Eike Sebastian Debus</dc:creator>
<dc:creator>Mark R Nehler</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:creator>Eva Muehlhofer</dc:creator>
<dc:creator>Lloyd P Haskell</dc:creator>
<dc:creator>Scott D Berkowitz</dc:creator>
<dc:creator>Rupert M Bauersachs</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD</dc:title>
<dc:identifier>pmid:38377256</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065330</dc:identifier>
</item>
<item>
<title>Cardiovascular Health Care in Low- and Middle-Income Countries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377254/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):557-559. doi: 10.1161/CIRCULATIONAHA.123.065717. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377254/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38377254</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065717>10.1161/CIRCULATIONAHA.123.065717</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377254</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Ana Olga Mocumbi</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Health Care in Low- and Middle-Income Countries</dc:title>
<dc:identifier>pmid:38377254</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065717</dc:identifier>
</item>
<item>
<title>Addressing Barriers to Entry and Retention of Women in Interventional Vascular Specialties With Proposed Solutions: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38375663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>Representation of women in interventional vascular fields (interventional cardiology, interventional radiology, and vascular surgery) lags behind that in other specialties. With women representing half of all medical school graduates, encouraging parity of women in these fields needs to start in medical school. Barriers to pursuing careers in vascular intervention include insufficient exposure during core clerkships, early mentorship, visibility of women in the field, length of training,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20. doi: 10.1161/CIR.0000000000001210. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Representation of women in interventional vascular fields (interventional cardiology, interventional radiology, and vascular surgery) lags behind that in other specialties. With women representing half of all medical school graduates, encouraging parity of women in these fields needs to start in medical school. Barriers to pursuing careers in vascular intervention include insufficient exposure during core clerkships, early mentorship, visibility of women in the field, length of training, lifestyle considerations, work culture and environment, and concerns about radiation exposure. This scientific statement highlights potential solutions for both the real and perceived barriers that women may face in pursuing careers in vascular intervention, including streamlining of training (as both interventional radiology and vascular surgery have done with a resultant increase in percentage of women trainees), standardization of institutional promotion of women in leadership, and professional and industry partnerships for the retention and advancement of women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38375663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38375663</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001210>10.1161/CIR.0000000000001210</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38375663</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>S Elissa Altin</dc:creator>
<dc:creator>Mimmie Kwong</dc:creator>
<dc:creator>Naomi M Hamburg</dc:creator>
<dc:creator>Mark A Creager</dc:creator>
<dc:creator>Subhash Banerjee</dc:creator>
<dc:creator>Lola Oladini</dc:creator>
<dc:creator>Marabel D Schneider</dc:creator>
<dc:creator>Jean Marie Ruddy</dc:creator>
<dc:creator>American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Stroke Council</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Addressing Barriers to Entry and Retention of Women in Interventional Vascular Specialties With Proposed Solutions: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38375663</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001210</dc:identifier>
</item>
<item>
<title>Gsα Regulates Macrophage Foam Cell Formation During Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38375634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Gsα activation is enhanced during atherosclerotic progression and increases lipid uptake and foam cell formation. The genetic or chemical inactivation of Gsα inhibit the development of atherosclerosis in mice, suggesting that drugs targeting Gsα may be useful in the treatment of atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 20. doi: 10.1161/CIRCRESAHA.123.323156. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many cardiovascular pathologies are induced by signaling through G-protein-coupled receptors via Gsα (G protein stimulatory α subunit) proteins. However, the specific cellular mechanisms that are driven by Gsα and contribute to the development of atherosclerosis remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: High-throughput screening involving data from single-cell and bulk sequencing were used to explore the expression of Gsα in atherosclerosis. The differentially expression and activity of Gsα were analyzed by immunofluorescence and cAMP measurements. Macrophage-specific Gsα knockout (Mac-Gsα<sup>KO</sup>) mice were generated to study the effect on atherosclerosis. The role of Gsα was determined by transplanting bone marrow and performing assays for foam cell formation, Dil-ox-LDL (oxidized low-density lipoprotein) uptake, chromatin immunoprecipitation, and luciferase reporter assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ScRNA-seq showed elevated <i>Gnas</i> in atherosclerotic mouse aorta's cholesterol metabolism macrophage cluster, while bulk sequencing confirmed increased <i>GNAS</i> expression in human plaque macrophage content. A significant upregulation of Gsα and active Gsα occurred in macrophages from human and mouse plaques. Ox-LDL could translocate Gsα from macrophage lipid rafts in short-term and promote <i>Gnas</i> transcription through ERK1/2 activation and C/EBPβ phosphorylation via oxidative stress in long-term. Atherosclerotic lesions from Mac-Gsα<sup>KO</sup> mice displayed decreased lipid deposition compared with those from control mice. Additionally, Gsα deficiency alleviated lipid uptake and foam cell formation. Mechanistically, Gsα increased the levels of cAMP and transcriptional activity of the cAMP response element binding protein, which resulted in increased expression of CD36 and SR-A1. In the translational experiments, inhibiting Gsα activation with suramin or cpGN13 reduced lipid uptake, foam cell formation, and the progression of atherosclerotic plaques in mice in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Gsα activation is enhanced during atherosclerotic progression and increases lipid uptake and foam cell formation. The genetic or chemical inactivation of Gsα inhibit the development of atherosclerosis in mice, suggesting that drugs targeting Gsα may be useful in the treatment of atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38375634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38375634</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323156>10.1161/CIRCRESAHA.123.323156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38375634</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Chang Ma</dc:creator>
<dc:creator>Yihui Li</dc:creator>
<dc:creator>Mi Tian</dc:creator>
<dc:creator>Qiming Deng</dc:creator>
<dc:creator>Qin Xiaoteng</dc:creator>
<dc:creator>Hanlin Lu</dc:creator>
<dc:creator>Jiangang Gao</dc:creator>
<dc:creator>Min Chen</dc:creator>
<dc:creator>Lee S Weinstein</dc:creator>
<dc:creator>Mei Zhang</dc:creator>
<dc:creator>Peili Bu</dc:creator>
<dc:creator>Jianmin Yang</dc:creator>
<dc:creator>Yun Zhang</dc:creator>
<dc:creator>Cheng Zhang</dc:creator>
<dc:creator>Wencheng Zhang</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Gsα Regulates Macrophage Foam Cell Formation During Atherosclerosis</dc:title>
<dc:identifier>pmid:38375634</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323156</dc:identifier>
</item>
<item>
<title>Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38374341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 19. doi: 10.1038/s41569-024-00999-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38374341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38374341</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00999-y>10.1038/s41569-024-00999-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38374341</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity</dc:title>
<dc:identifier>pmid:38374341</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00999-y</dc:identifier>
</item>
<item>
<title>Weight loss from surgery or drug therapy reduces blood pressure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38374340/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 19. doi: 10.1038/s41569-024-01000-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38374340/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38374340</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01000-6>10.1038/s41569-024-01000-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38374340</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Weight loss from surgery or drug therapy reduces blood pressure</dc:title>
<dc:identifier>pmid:38374340</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01000-6</dc:identifier>
</item>
<item>
<title>Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>CD4^(+) T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 16:S0092-8674(24)00105-3. doi: 10.1016/j.cell.2024.01.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CD4<sup>+</sup> T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered in combination with pegylated interferon-α2a, induces a structural transformation of the HIV-1 reservoir cell pool, characterized by a disproportionate overrepresentation of HIV-1 proviruses integrated in ZNF genes and in chromatin regions with reduced H3K27ac marks, the molecular target sites for panobinostat. By contrast, proviruses near H3K27ac marks were actively selected against, likely due to increased susceptibility to panobinostat. These data suggest that latency-reversing treatment can increase the immunological vulnerability of HIV-1 reservoir cells and accelerate the selection of epigenetically privileged HIV-1 proviruses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38367616</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.037>10.1016/j.cell.2024.01.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367616</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Marie Armani-Tourret</dc:creator>
<dc:creator>Ce Gao</dc:creator>
<dc:creator>Ciputra Adijaya Hartana</dc:creator>
<dc:creator>WeiWei Sun</dc:creator>
<dc:creator>Leah Carrere</dc:creator>
<dc:creator>Liliana Vela</dc:creator>
<dc:creator>Alexander Hochroth</dc:creator>
<dc:creator>Maxime Bellefroid</dc:creator>
<dc:creator>Amy Sbrolla</dc:creator>
<dc:creator>Katrina Shea</dc:creator>
<dc:creator>Theresa Flynn</dc:creator>
<dc:creator>Isabelle Roseto</dc:creator>
<dc:creator>Yelizaveta Rassadkina</dc:creator>
<dc:creator>Carole Lee</dc:creator>
<dc:creator>Francoise Giguel</dc:creator>
<dc:creator>Rajeev Malhotra</dc:creator>
<dc:creator>Frederic D Bushman</dc:creator>
<dc:creator>Rajesh T Gandhi</dc:creator>
<dc:creator>Xu G Yu</dc:creator>
<dc:creator>Daniel R Kuritzkes</dc:creator>
<dc:creator>Mathias Lichterfeld</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a</dc:title>
<dc:identifier>pmid:38367616</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.037</dc:identifier>
</item>
<item>
<title>The genetic changes that shaped Neandertals, Denisovans, and modern humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>Modern human ancestors diverged from the ancestors of Neandertals and Denisovans about 600,000 years ago. Until about 40,000 years ago, these three groups existed in parallel, occasionally met, and exchanged genes. A critical question is why modern humans, and not the other two groups, survived, became numerous, and developed complex cultures. Here, we discuss genetic differences among the groups and some of their functional consequences. As more present-day genome sequences become available...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 14:S0092-8674(23)01403-4. doi: 10.1016/j.cell.2023.12.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Modern human ancestors diverged from the ancestors of Neandertals and Denisovans about 600,000 years ago. Until about 40,000 years ago, these three groups existed in parallel, occasionally met, and exchanged genes. A critical question is why modern humans, and not the other two groups, survived, became numerous, and developed complex cultures. Here, we discuss genetic differences among the groups and some of their functional consequences. As more present-day genome sequences become available from diverse groups, we predict that very few, if any, differences will distinguish all modern humans from all Neandertals and Denisovans. We propose that the genetic basis of what constitutes a modern human is best thought of as a combination of genetic features, where perhaps none of them is present in each and every present-day individual.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38367615</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.029>10.1016/j.cell.2023.12.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367615</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Hugo Zeberg</dc:creator>
<dc:creator>Mattias Jakobsson</dc:creator>
<dc:creator>Svante Pääbo</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The genetic changes that shaped Neandertals, Denisovans, and modern humans</dc:title>
<dc:identifier>pmid:38367615</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.029</dc:identifier>
</item>
<item>
<title>Tackling metabolic defects in HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 17:ehad884. doi: 10.1093/eurheartj/ehad884. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38367012</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad884>10.1093/eurheartj/ehad884</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367012</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Rongling Wang</dc:creator>
<dc:creator>Gabriele G Schiattarella</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tackling metabolic defects in HFpEF</dc:title>
<dc:identifier>pmid:38367012</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad884</dc:identifier>
</item>
<item>
<title>The Canadian Cardiovascular Society Classification of acute atherothrombotic myocardial infarction provides a novel staging scheme based on tissue injury severity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 17:ehad821. doi: 10.1093/eurheartj/ehad821. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38367011</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad821>10.1093/eurheartj/ehad821</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367011</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Andreas Kumar</dc:creator>
<dc:creator>Keyur Vora</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Rohan Dharmakumar</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Canadian Cardiovascular Society Classification of acute atherothrombotic myocardial infarction provides a novel staging scheme based on tissue injury severity</dc:title>
<dc:identifier>pmid:38367011</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad821</dc:identifier>
</item>
<item>
<title>Breathing danger: linking air pollution to cardiovascular disease and increased risk of abdominal aortic aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae092. doi: 10.1093/eurheartj/ehae092. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38366825</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae092>10.1093/eurheartj/ehae092</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366825</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Omar Hahad</dc:creator>
<dc:creator>Andreas Daiber</dc:creator>
<dc:creator>Thomas Münzel</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Breathing danger: linking air pollution to cardiovascular disease and increased risk of abdominal aortic aneurysm</dc:title>
<dc:identifier>pmid:38366825</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae092</dc:identifier>
</item>
<item>
<title>A new dawn of managing cardiovascular risk in obesity: the importance of combining lifestyle intervention and medication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366823/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae091. doi: 10.1093/eurheartj/ehae091. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366823/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38366823</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae091>10.1093/eurheartj/ehae091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366823</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Martin Halle</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A new dawn of managing cardiovascular risk in obesity: the importance of combining lifestyle intervention and medication</dc:title>
<dc:identifier>pmid:38366823</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae091</dc:identifier>
</item>
<item>
<title>Device innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366821/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence and machine learning. There is a need to foster an environment conducive to medical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae069. doi: 10.1093/eurheartj/ehae069. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence and machine learning. There is a need to foster an environment conducive to medical technology development and validation so that Europe can continue to play a major role in device innovation while providing high standards of safety. This paper summarizes viewpoints on the topic of device innovation in cardiovascular medicine at the European Society of Cardiology Cardiovascular Round Table, a strategic forum for high-level dialogue to discuss issues related to the future of cardiovascular health in Europe. Devices are developed and improved through an iterative process throughout their lifecycle. Early feasibility studies demonstrate proof of concept and help to optimize the design of a device. If successful, this should ideally be followed by randomized clinical trials comparing novel devices vs. accepted standards of care when available and the collection of post-market real-world evidence through registries. Unfortunately, standardized procedures for feasibility studies across various device categories have not yet been implemented in Europe. Cardiovascular imaging can be used to diagnose and characterize patients for interventions to improve procedural results and to monitor devices long term after implantation. Randomized clinical trials often use cardiac imaging-based inclusion criteria, while less frequently trials randomize patients to compare the diagnostic or prognostic value of different modalities. Applications using machine learning are increasingly important, but specific regulatory standards and pathways remain in development in both Europe and the USA. Standards are also needed for smart devices and digital technologies that support device-driven biomonitoring. Changes in device regulation introduced by the European Union aim to improve clinical evidence, transparency, and safety, but they may impact the speed of innovation, access, and availability. Device development programmes including dialogue on unmet needs and advice on study designs must be driven by a community of physicians, trialists, patients, regulators, payers, and industry to ensure that patients have access to innovative care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366821/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38366821</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae069>10.1093/eurheartj/ehae069</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366821</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Stephan Achenbach</dc:creator>
<dc:creator>Alain Cribier</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Nataliya Deych</dc:creator>
<dc:creator>Inga Drossart</dc:creator>
<dc:creator>Hélène Eltchaninoff</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:creator>Alexandra Goncalves</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Richard Holborow</dc:creator>
<dc:creator>Arie Pieter Kappetein</dc:creator>
<dc:creator>John Kilmartin</dc:creator>
<dc:creator>Jana Kurucova</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Donal B O'Connor</dc:creator>
<dc:creator>Mark Perkins</dc:creator>
<dc:creator>Eigil Samset</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Device innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table</dc:title>
<dc:identifier>pmid:38366821</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae069</dc:identifier>
</item>
<item>
<title>Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae068. doi: 10.1093/eurheartj/ehae068. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38366820</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae068>10.1093/eurheartj/ehae068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366820</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Robert A Hegele</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?</dc:title>
<dc:identifier>pmid:38366820</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae068</dc:identifier>
</item>
<item>
<title>Anticoagulation in atrial fibrillation and implantable cardioverter defibrillator implantation in arrhythmogenic right ventricular cardiomyopathy: need for improving patient selection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16;45(7):491-494. doi: 10.1093/eurheartj/ehae070.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38366819</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae070>10.1093/eurheartj/ehae070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366819</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation in atrial fibrillation and implantable cardioverter defibrillator implantation in arrhythmogenic right ventricular cardiomyopathy: need for improving patient selection</dc:title>
<dc:identifier>pmid:38366819</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae070</dc:identifier>
</item>
<item>
<title>Correction to: Cardiovascular hospitalizations and mortality among adults aged 25-64 years in the USA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366817/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240220193753&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae018. doi: 10.1093/eurheartj/ehae018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366817/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240220193753&v=2.18.0.post9+e462414">38366817</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae018>10.1093/eurheartj/ehae018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366817</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Cardiovascular hospitalizations and mortality among adults aged 25-64 years in the USA</dc:title>
<dc:identifier>pmid:38366817</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae018</dc:identifier>
</item>





























</channel>
</rss>